GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
Three New Studies Initiated in Other Oncology Settings
LONDON and COPENHAGEN, Denmark, Jan. 30 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab
A/S (OMX: GEN) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...
Medarex Announces 2008 Fourth Quarter and Year End Financial Results
...hare, from Medarex's sale of 2.5 million shares of genmab
A/S ("Genmab") stock in February 2008; a non-cash ...fair market value of Medarex's equity interests in genmab
and Celldex were approximately $87.4 million and a... million through the sale of 2.5 million shares of genmab
A/S common stock, reducing our ownership in...
Genmab Announces 2008 First Half Year Results
... Summary: genmab
Reports Results for the Six Month Period Ended Jun...
COPENHAGEN, August 27 /PRNewswire-FirstCall/ -- genmab
A/S (OMX: GEN)
announced today results for the six...th period ended June 30, 2008.
During this period, genmab
reported the following results:
Medarex Announces 2008 First Quarter Financial Results
...hare, from Medarex's
sale of 2.5 million shares of genmab
A/S stock in February 2008, Medarex's
net income f...od in 2007. In addition to the gain on the sale
A/S stock, Medarex's net income for the quarter en... fair market value of Medarex's equity interest in genmab
approximately $115.6 million as of March 31, 2...
QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
...rp. (Nasdaq: ARTC ) Endo Pharmaceuticals Hldgs. (Nasdaq: ENDP ) Fresenius Medical Care AG (XETRA: FME.DE) GEDEON RICHTER RT (XETRA: R1G1.DE) genmab
A/S (Copenhagen: GEN.CO) H. LUNDBECK A/S (Copenhagen: LUN.CO) Human Genome Sciences (Nasdaq: HGSI ) Imclone Systems (Nasdaq: IMCL ) Invernes...
Medarex Announces 2007 Fourth Quarter and Year End Financial Results
sale of approximately 2.6 million shares of genmab
A/S stock in February
2007, Medarex's net loss for... fair market value of Medarex's
equity interest in genmab
was approximately $291.2 million as of December
31... the sale of approximately 2.6 million shares of genmab
A/S common stock.
"We enter 2008 with great ...
Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
... Summary: genmab
has Initiated a Phase II Study of Ofatumumab in Re...EN, Denmark, December 13 /PRNewswire-FirstCall/ -- genmab
(OMX: GEN) announced today that study centers ...evelopment and commercialization agreement
"We have now expanded the o...
Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
... Summary: genmab
and GSK Have Announced the Initiation of the Phase...EN, Denmark, November 20 /PRNewswire-FirstCall/ -- genmab
(OMX: GEN) and GlaxoSmithKline (LSE and NYSE: ... "We are very pleased that our collaboration with genmab
so that we can now move to the next...
Genmab in Medical Technology
Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
Review Zanolimumab Program to be Discontinued and Headcount to be Reduced
Announces the Results of its Portfolio Review; Zanolimumab Program to be Discontinued and the Company Will Reduce the Number of Employees
COPENHAGEN, October 8 /PRNewswire-F...
Bionomics Achieves US$1 Million Milestone Payment from Genmab
ADELAIDE and COPENHAGEN, Feb. 19 /PRNewswire-FirstCall/ -- Bionomics
Limited (ASX: BNO, US OTC: BMICY) today announced the successful completion
of pre-clinical testing on the first of eight proteins licensed to US $2.6
billion Danish antibody company Genmab
A/S (OMX: GEN), triggering a US $1
New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study
in Rheumatoid Arthritis to be Presented at EULAR
COPENHAGEN, Denmark; April 25, 2007 - Genmab
A/S (CSE: GEN)
announced today that the results of a Phase II study with
ofatumumab (HuMax-CD20™) in patients with rheumatoid
arthritis (RA) have been accepted for oral presentation at the 2007
Annual European Congress of Rheumatology (EULAR). The...
GlaxoSmithKline and Genmab Present Positive Phase II Results With
ofatumumab in Patients With Rheumatoid Arthritis (RA)
New Data to be Presented at the European League Against Rheumatism
(EULAR) Congress Demonstrates the Potential Benefit of ofatumumab
in Patients With Rheumatoid Arthritis
LONDON, England; PHILADELPHIA, Pennsylvania and COPENHAGEN,
Denmark, June 15, 2007 /PRNewswire-FirstCall/ -- GlaxoSmithKline
FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)
...wire-FirstCall/ -- GlaxoSmithKline [NYSE: GSK] and genmab
A/S [OMX: GEN] today announced that the United Sta...rs of dedicated research and collaboration between genmab
The advisory committee made its de...b is being developed under a collaboration between genmab
and the GSK Oncology and BioPharm R&D Units.
Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
...RNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and genmab
A/S (OMX: GEN) announced today positive results fr...ly collaborating on filing submissions."
and GSK now expect to file a Biologics License App...evelopment and commercialization agreement between genmab
and GlaxoSmithKline. It is not yet approved for an...
Recruitment Completed in Ofatumumab NHL Pivotal Study
... Summary: genmab
has Completed Recruitment of Patients in the Phase...COPENHAGEN, September 23 /PRNewswire-FirstCall/ -- genmab
GEN) announced today it has completed re...evelopment and commercialization
agreement between genmab
and GlaxoSmithKline. It is not yet approved for
Genmab Announces Upcoming Ofatumumab Studies
...AGEN, Denmark, August 25 /PRNewswire-FirstCall/ -- genmab
announced plans to begin four studies of ofatu...lymphocytic
leukemia and non-Hodgkin's lymphoma.
A/S (OMX: GEN) announced today plans to begin four...evelopment and commercialization agreement between genmab
GlaxoSmithKline. It is not yet approved in any...
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
COPENHAGEN, July 31 /PRNewswire-FirstCall/ -- genmab
A/S (OMX: GEN) and
GlaxoSmithKline (LSE and NYSE: ...This also represents a significant achievement for genmab
now move toward filing of the first marketin...t and
Medicine Development Leader at GSK. "GSK and genmab
are collaborating on a
comprehensive development p...
Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study
...ne and cyclophosphamide to treat front line
A/S (OMX: GEN) announced today it has completed re...evelopment and commercialization agreement
and GlaxoSmithKline. It is not yet approved in any...d at any time during the treatment
Genmab in Biological Technology
Passing of Genmab A/S' Annual General Meeting
COPENHAGEN, April 23 /PRNewswire-FirstCall/ -- Summary: At Genmab
Annual General Meeting held today on April 23, 2008 the Annual Report for
2007 was approved, discharge was given to the Board of Directors and the
Management and the year's loss was carried forward. Two members of the
Medarex Announces Completion of Sale of Shares in Genmab A/S
PRINCETON, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX ) announced today that it has completed the sale of
approximately 2.5 million shares of Genmab
A/S which stock is traded on the
Copenhagen Stock Exchange. The trade is expected to settle on February 1,
Roche Files IND for Second Genmab Antibody
Summary: Genmab's Partner Roche has Filed an IND With the US FDA for a Genmab
COPENHAGEN, August 10 /PRNewswire-FirstCall/ -- Genmab
A/S (OMX: GEN)
announced today that its partner Roche has filed an Investigational New
Drug application (IND) with the US Fo...
Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Summary: An IND has Been Filed With the FDA for the Fourth Genmab
Antibody Developed Under the Company's Collaboration with Roche.
COPENHAGEN, December 12 /PRNewswire-FirstCall/ -- Genmab
A/S (OMX: GEN)
announced today that an Investigational New Drug application (IND) for a
Pepscan Achieves First Milestone in Research Collaboration With Genmab
LELYSTAD, The Netherlands, March 10 /PRNewswire/ -- Pepscan Therapeutics
(Pepscan) today announced that it has earned a milestone payment from Genmab
A/S. The milestone payment arises from an ongoing Research Collaboration
aimed at identifying human antibodies against intractable targets. Peps...
Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium
...e more reticent. They are looking at a completely different risk-reward equation."
Symposium panelists also included: Annarie Lyles , Ph.D., genmab
, Senior Vice President/Head of Business Development; Andrew Reaume , Ph.D., M.B.A., Melior Discovery , President/CEO; Evan Myrianthopoulos ...
Medarex Announces 2009 First Quarter Financial Results
... per share, from the sale of 2.5 million shares of genmab
A/S stock in February 2008. Medarex's net loss for...fair market value of Medarex's equity interests in genmab
and Celldex Therapeutics were approximately $85.3 ...4,490 67,154
Marketable securities - genmab
Ernst & Young Benchmarks Danish Biotech Pipeline Third in Europe
...stronger" prepared in cooperation with the Danish
Association of Biotechnology Industries.
"Being a global biotech company founded in Denmark, genmab
is proud to be
part of the important Medicon Valley biotech sector. We have found the
innovative climate inspiring in the process of building our late...
Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH
... COPENHAGEN, November 10 /PRNewswire-FirstCall/ -- genmab
A/S (OMX: GEN)
announced today that three ofatumum...evelopment and commercialization agreement between genmab
GlaxoSmithKline. It is not yet approved for sale in any country.
Medarex Announces 2008 Third Quarter Financial Results
...fair market value of Medarex's equity
interests in genmab
A/S and Celldex Therapeutics, Inc. were approximat... - 14,000 Marketable securities - genmab
- 152,000 Other c... 72,127 79,925 Marketable securities - genmab
non-current 131,704 139,165 Investm...